Full text is available at the source.
Abstract
MP2 lipid nanoparticles (LNPs) demonstrated a 15-fold higher delivery efficiency in vivo compared to FDA-approved SM102 LNPs.
- MP2 LNPs, when loaded with interleukin-35 (IL-35) mRNA, improved clinical outcomes in mouse models of acute and chronic inflammatory bowel disease (IBD).
- Treatment with MP2-IL-35 LNPs resulted in preserved colon length and decreased levels of pro-inflammatory cytokines.
- In human colonic biopsies, MP2 LNPs were effective in delivering mRNA to immune, epithelial, and endothelial cells.
- MP2-IL-35 LNPs significantly altered the subsets of effector and regulatory T cells in biopsies from patients with IBD.
Simplified